GentiBio raises $157m through Series A funding round

GentiBio通过A轮融资筹集了1.57亿美元

2021-08-12 22:30:16 PHARMACEUTICAL

本文共782个字,阅读需2分钟

Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the round to advance its new pipeline of engineered regulatory T cell (Treg) treatments in immunology. The round also saw participation of Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, Novartis Venture Fund and Seattle Children’s Research Institute. Set up in August 2020 GentiBio had raised $20m of seed funding from OrbiMed, Novartis Venture Fund and RA Capital. The firm’s platform is intended to functionally treat autoimmune, alloimmune, autoinflammatory and allergic conditions. It taps new technologies that redirect stable, potent engineered Tregs to tissues damaged because of abnormal immune responses. With this platform, GentiBio can make several tuneable Treg phenotypes from rich autologous and allogeneic cell sources that can be generated at scale. Following the latest funding round, the company has so far raised $177m since its launch. The firm intends to use proceeds from the Series A funding to advance its potential functional cure for type 1 diabetes (T1D) to clinical trials along with several other pipeline programmes in chronic autoimmunity and autoinflammation. Currently, the company is selecting its clinical candidate for T1D and will begin investigational new drug (IND)-enabling trials before the end of this year. GentiBio president and CEO Adel Nada said: “GentiBio engineered Tregs created from abundant autologous and allogeneic T cell sources have the potential to overcome scalability and phenotypic inconsistency issues that are intrinsic to Tregs sorted from peripheral blood. “With the Series A financing, we are focused on advancing our programmes with a uniquely scalable manufacturing process that produces stable and disease-specific engineered Tregs that are also tunable once infused in patients.” Andy Tran from Matrix Capital will join GentiBio’s board of directors as part of its funding.
生物治疗公司GentiBio通过由Matrix Capital Management牵头的a轮融资筹集了1.57亿美元。 该公司计划利用这一轮的收益来推进其免疫学中工程调节性T细胞(Treg)治疗的新管道。 Avidity Partners、JDRF T1D Fund、OrbiMed、RA Capital Management、Novartis Venture Fund和西雅图儿童研究所也参与了这一轮。 GentiBio成立于2020年8月,从OrbiMed、诺华风险基金和RA Capital筹集了2000万美元的种子资金。 该公司的平台旨在功能性治疗自身免疫性、同种免疫性、自身炎症和过敏性疾病。 它利用新技术将稳定、有效的工程Tregs重定向到因异常免疫反应而受损的组织。 利用该平台,GentiBio可以从丰富的自体和异体细胞源中制作几种可调谐的Treg表型,这些细胞源可以规模化生成。 在最近一轮融资后,该公司自成立以来已筹集了1.77亿美元。 该公司打算利用A系列资金的收益,将其对1型糖尿病(T1D)的潜在功能性治疗推进到临床试验,以及其他几个慢性自身免疫和自身炎症的管道项目。 目前,该公司正在为T1D选择临床候选药物,并将在今年年底前开始研究性新药(IND)启动试验。 GentiBio总裁兼首席执行官阿黛尔·纳达(Adel Nada)表示:“从丰富的自体和异体T细胞来源中创建的GentiBio工程Tregs有潜力克服从外周血中分离的Tregs固有的可扩展性和表型不一致问题。 “通过A系列融资,我们专注于推进我们的项目,采用独特的可扩展制造工艺,生产稳定和针对疾病的工程Tregs,一旦注入患者体内,这些工程Tregs也可以调节。” 矩阵资本的安迪·陈(Andy Tran)将加入Gentibio的董事会,作为其资金的一部分。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文